Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.
LUMO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for LUMO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Lumos Pharma Inc ranked in the 7th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 96.33%. In terms of the factors that were most noteworthy in this DCF analysis for LUMO, they are:
The company's compound free cash flow growth rate over the past 5.51 years comes in at -0.37%; that's greater than only 3.96% of US stocks we're applying DCF forecasting to.
Relative to other stocks in its sector (Healthcare), Lumos Pharma Inc has a reliance on debt greater than just 6.67% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
INFU, NVST, PHG, PPD, and SXTC can be thought of as valuation peers to LUMO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.H.C. Wainwright BioConnect 2021 Conference Date:January 11, 2021 What:Lumos Pharma Presentation A webcast of Lumos Pharma’s presentation will be available on-demand as of 6:00AM ET, Monday, January 11, 2021, through the H.C. Wainwright conference portal and on Lumos Pharma’s website under “Events & Presentations” in the Investors & Media section. The webcast will be available on Lumos Pharma’s website for 30 days. No one-on-one meetings will be held at the presentation - o...
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]
* Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the third quarter ended September 30, 2020 and provided an update on clinical activities.“This past quarter was marked by significant achievements leading to the initiation of our Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency patients and the previously announced sale of our PRV in July,” commented Rick Hawkins, Chairman, CEO and President of Lumos Pharma. “We are th...
NEW YORK, NY / ACCESSWIRE / November 10, 2020 / Lumos Pharma Inc (NASDAQ:LUMO) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 10, 2020 at 4:30 PM Eastern Time.